MCK Call Options: Riding the Bullish Momentum with AI

McKesson Corporation is a diversified healthcare services leader. Its core business segments include U.S. Pharmaceutical, Prescription Technology Solutions ('RxTS'), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes pharmaceutical drugs and provides solutions to pharmacies, hospitals, and specialty practices, including services through 'McKesson Connect SM'. 'RxTS' connects patients, pharmacies, providers, and biopharma companies to improve medication access. The Medical-Surgical Solutions segment offers medical supply distribution to healthcare providers, offering both national brands and 'McKesson's own line' of products. The International segment provides distribution and services in Canada and Norway, with retail pharmacies operating under banners such as 'IDA', 'Guardian', 'The Medicine Shoppe', 'Remedy'sRx', 'Proxim', and 'Uniprix'. McKesson differentiates itself through its scale, diverse product and service offerings, innovation, and adoption of new technologies.

No relevant news was found for this stock today.

MCK's technical outlook is moderately bullish. The stock is currently trading at $842.52, significantly above its 50-day SMA of $743.98 and 200-day SMA of $693.94, signaling a strong upward trend. The 21-day EMA is at $789.13 and rising. The MACD at 20.67 is well above its signal line (19.83) with a positive MACDh of 0.84, indicating strong bullish momentum. The RSI is at 67.04, suggesting the stock is approaching overbought conditions but still has room to run. The STOCHk is at 66.74, with STOCHd at 76.12, indicating potential for further upside. The ADX is at 32.63, showing a strong trend. The recent price action shows a breakout to a new 52-week high, further supporting the bullish sentiment. While a pullback is possible, the overall trend and momentum suggest continued upward movement over the next 1-3 months.

McKesson's MD&A presents a mixed financial picture for the three months ended June 30, 2025. `Revenues` increased by 23% compared to the prior year, driven primarily by growth in the U.S. Pharmaceutical segment, which saw a 25% increase. However, `Gross profit` only increased by 4%, with the `Gross profit margin` decreasing by 63 basis points to 3.35%. The US Pharmaceutical segment was impacted by a $189 million provision for bad debts related to Rite Aid's bankruptcy. The company also completed acquisitions of PRISM Vision and Core Ventures for $874 million and $2.5 billion in cash, respectively. `Net cash used by operating activities` was $918 million, an improvement compared to the $1.4 billion used in the same period last year. The company returned $671 million to shareholders through share repurchases and dividends. Management expects cash from operations, short-term investments, credit facilities, and other borrowings to be sufficient to fund short-term and long-term capital expenditures. The Board raised the quarterly dividend to $0.82 per share, signaling confidence, but the Rite Aid bankruptcy and acquisition costs create uncertainty.

McKesson's Q1 fiscal 2026 earnings call projects a moderately bullish outlook. The company reported strong Q1 results, with CEO Brian Tyler highlighting 'record consolidated revenues of $97.8 billion, an increase of 23% over the prior year.' The company raised its full-year guidance to $37.10 to $37.90 from a previous range of $36.90 to $37.70. Three segments delivered double-digit growth in adjusted operating profit. CFO Britt Vitalone noted that the U.S. Pharmaceutical segment revenues increased 25%, driven by increased prescription volumes and growth in oncology and specialty products. They also entered into an agreement to sell their Norway retail and distribution businesses, expecting a $0.20 adjusted earnings per diluted share impact, included in the updated full-year guidance. While the call acknowledged the potential impact of Medicaid cuts, management anticipates it will not be dramatic. Overall, the tone suggests confidence in McKesson's strategic direction and ability to deliver shareholder value.

MCK's financial performance presents a mixed but slightly positive picture. Revenue has generally increased, starting from $76.355B in Q4 2024 and reaching $97.827B in Q1 2026, indicating growth in sales. The gross profit ratio has fluctuated, ranging from 0.0335 in the most recent quarter to 0.0453 in Q4 2024, suggesting some variability in profitability. Operating cash flow has been inconsistent, with a significant negative value of -$1.38B in Q1 2025, followed by a strong positive $7.748B in Q4 2025 but then dropping back down to -$918M in the latest quarter. Total debt has increased from $7.39B in Q4 2024 to $9.933B in Q1 2026, signaling increased leverage. While revenue growth is a positive sign, the fluctuating profitability and operating cash flow, coupled with the increasing debt, warrant careful monitoring over the next 12 months. The most recent negative operating cash flow is a concern and needs to be addressed to ensure financial stability.

The company demonstrates a moderately bullish profile, characterized by solid revenue growth and improving profitability. Revenue has consistently increased, indicating strong market demand. The gross margin exhibits stability, suggesting efficient cost management. Return on Equity (ROE) has shown positive movement, signaling enhanced profitability and efficient use of shareholder equity. The Price-to-Earnings (P/E) ratio, while elevated, might be justifiable given the growth trajectory and positive ROE trend. The Debt-to-Equity ratio shows a slight increase, which warrants monitoring, but is counterbalanced by a healthy Current Ratio, implying sufficient liquidity to meet short-term obligations. Overall, the company presents a favorable picture with growth and profitability, though the leverage should be watched closely. The combination of growth and profitability suggests potential for continued positive performance over the next 12 months.